Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) and PetVivo (NASDAQ:PETV – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Nihon Kohden and PetVivo, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nihon Kohden | 0 | 1 | 0 | 1 | 3.00 |
| PetVivo | 0 | 0 | 0 | 0 | 0.00 |
Valuation and Earnings
This table compares Nihon Kohden and PetVivo”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nihon Kohden | $1.56 billion | 1.02 | $95.79 million | $0.55 | 17.25 |
| PetVivo | $1.05 million | 25.03 | -$10.95 million | ($0.38) | -1.82 |
Nihon Kohden has higher revenue and earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
0.1% of Nihon Kohden shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 10.8% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Nihon Kohden and PetVivo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nihon Kohden | 5.90% | 9.08% | 6.37% |
| PetVivo | -902.82% | -4,813.07% | -281.78% |
Volatility & Risk
Nihon Kohden has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Summary
Nihon Kohden beats PetVivo on 9 of the 13 factors compared between the two stocks.
About Nihon Kohden
Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.
About PetVivo
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Nihon Kohden Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nihon Kohden and related companies with MarketBeat.com's FREE daily email newsletter.
